Columbia University/Herbert Irving Comprehensive Cancer Center

New York, New York 10032

4 studies enrolling now · 21 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Breast Cancer, Advanced Cancer, Advanced Melanoma, Advanced Solid Tumors, Aggressive Lymphoma, Anogenital Cancers, B-cell Malignancies, Bladder Cancer, Brain Tumor, Breast Cancer, CCNE1 Amplification

Studies at this site

• A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy — Recruiting now
• A Study of ASP3082 in Adults With Advanced Solid Tumors — Recruiting now
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer — Recruiting now
• Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors — Recruiting now
• Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome — Running, not enrolling
• Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Running, not enrolling
• (VELA) Study of BLU-222 in Advanced Solid Tumors — Stopped early
• A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors — Running, not enrolling
• A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors — Running, not enrolling
• A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) — Completed
• INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma — Completed
• CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma — Stopped early
• A Study Of The Selective PKC-β Inhibitor MS- 553 — Stopped early
• Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma — Completed
• Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia — Stopped early
• FHD-286 in Subjects With Metastatic Uveal Melanoma — Stopped early
• Evaluation of NanoDoce® in Participants With Urothelial Carcinoma — Completed
• Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas — Stopped early
• Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma — Completed
• PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy — Completed
• Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies — Completed